Dr. Frederick LANSIGAN, MD
Claim this profileDartmouth Hitchcock Medical Center
Expert in Lymphoma
Studies B-Cell Lymphoma
11 reported clinical trials
30 drugs studied
Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
CCND1 positive
2B-Cell Lymphoma
CCND1 positive
t(11;14) positive
CD20 positive
Affiliated Hospitals
Clinical Trials Frederick LANSIGAN, MD is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
Rituximab + Stem Cell Transplant
for Mantle Cell Lymphoma
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
Recruiting2 awards Phase 3
More about Frederick LANSIGAN, MD
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Frederick LANSIGAN, MD has experience with
- Nivolumab
- Rituximab
- Cyclophosphamide
- Doxorubicin Hydrochloride
- Obinutuzumab
- Lenalidomide
Breakdown of trials Frederick LANSIGAN, MD has run
Lymphoma
B-Cell Lymphoma
Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Frederick LANSIGAN, MD specialize in?
Frederick LANSIGAN, MD focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Frederick LANSIGAN, MD currently recruiting for clinical trials?
Yes, Frederick LANSIGAN, MD is currently recruiting for 4 clinical trials in Lebanon New Hampshire. If you're interested in participating, you should apply.
Are there any treatments that Frederick LANSIGAN, MD has studied deeply?
Yes, Frederick LANSIGAN, MD has studied treatments such as Nivolumab, Rituximab, Cyclophosphamide.
What is the best way to schedule an appointment with Frederick LANSIGAN, MD?
Apply for one of the trials that Frederick LANSIGAN, MD is conducting.
What is the office address of Frederick LANSIGAN, MD?
The office of Frederick LANSIGAN, MD is located at: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756 United States. This is the address for their practice at the Dartmouth Hitchcock Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.